Company Overview

Guided Therapeutics, Inc. (OTCQB: GTHP) is a medical technology company focused on the development and commercialization of diagnostic devices intended to improve the early detection of cervical disease and cervical cancer. The company operates within the healthcare technology and medical diagnostics industries, with its primary emphasis on non-invasive screening technologies for women’s health. Its principal product platform has been the LuViva Advanced Cervical Scan, a device designed to identify cervical abnormalities using optical spectroscopy without requiring tissue removal or laboratory processing during the initial screening step.

The company’s core business model has centered on commercialization, regulatory advancement, and licensing opportunities tied to the LuViva platform and related intellectual property. Guided Therapeutics historically targeted healthcare providers, women’s health clinics, and international screening programs, particularly in markets where access to conventional cytology-based screening infrastructure is limited. The company was founded in the 1990s and evolved from a development-stage medical device enterprise into a commercialization-focused organization pursuing regulatory approvals, distribution relationships, and international market expansion for cervical cancer detection technologies.

Business Operations

Guided Therapeutics has historically operated primarily through a single medical diagnostics business segment focused on cervical cancer screening technologies. Revenue generation has been limited and has generally been associated with device sales, distribution arrangements, technology licensing, and related commercialization activities tied to the LuViva Advanced Cervical Scan system. Public filings indicate that the company has devoted substantial resources to product development, clinical testing, regulatory compliance, and manufacturing readiness rather than broad-scale recurring commercial operations.

The company’s operations have included activities in both the United States and select international markets, particularly through distributors and strategic commercial relationships. Guided Therapeutics has controlled proprietary optical spectroscopy technology and related patents associated with cervical tissue analysis. Public disclosures have referenced manufacturing and distribution partnerships intended to support international commercialization efforts, although the scale and continuity of these arrangements have varied over time. Data regarding active large-scale joint ventures or substantial operating subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Guided Therapeutics’ strategic direction has historically focused on expanding adoption of the LuViva platform as an alternative or complementary cervical cancer screening tool, especially in regions with limited laboratory infrastructure or low screening compliance rates. The company has pursued regulatory approvals, clinical validation studies, and international commercialization agreements as key growth initiatives. Publicly available filings and investor disclosures indicate an emphasis on demonstrating the technology’s ability to provide immediate screening results while reducing unnecessary follow-up procedures.

The company has also pursued intellectual property development and technology protection as part of its strategic positioning within the women’s health diagnostics market. While Guided Therapeutics has explored international distribution opportunities and financing arrangements, publicly available information does not indicate a broad portfolio of major acquisitions or diversified subsidiary investments comparable to larger medical technology companies. The company’s principal strategic asset remains the LuViva Advanced Cervical Scan technology platform and its associated patents and regulatory efforts.

Geographic Footprint

Guided Therapeutics is headquartered in Norcross, Georgia, United States, and has historically focused on commercialization opportunities in both domestic and international healthcare markets. Public company disclosures have identified interest in expanding into regions where cervical cancer screening access remains limited, including portions of Asia, Latin America, and other emerging healthcare markets.

The company’s operational footprint has primarily relied on distribution partnerships and regulatory initiatives rather than extensive physical international infrastructure. Its international strategy has generally centered on obtaining approvals and forming local commercial relationships to support adoption of the LuViva system outside the United States. Available public information indicates that international commercialization efforts have varied over time depending on financing conditions, regulatory progress, and operational capacity.

Leadership & Governance

Guided Therapeutics has been led by executives with backgrounds in medical devices, healthcare technology commercialization, and corporate finance. The company’s governance and leadership strategy has historically emphasized regulatory advancement, clinical validation, intellectual property development, and international commercialization of its cervical cancer detection technology.

Key executives and leadership figures identified in public filings and corporate disclosures include:

• Gene Cartwright – Founder and former executive leadership figure
• Mark L. Faupel – Former Chief Executive Officer
• Michael A. Cogdill – Former Chief Financial Officer
• Robert J. Cohen – Former Chairman and board leadership participant

Public filings, including disclosures associated with SEC filings, indicate that leadership priorities have consistently focused on advancing the commercialization potential of the company’s optical diagnostic technologies while managing financing requirements associated with a development-stage medical technology business. Some executive and board roles have changed periodically, and certain historical leadership data may vary across reporting periods.